Zymeworks Announces Second Janssen Bispecific Antibody to Begin Clinical Development Utilizing Azymetric ™ and EFECT ™ Therapeutic Platforms

Wednesday, December 1, 2021 1 min read

Key Takeaway: Zymeworks Announces Second Janssen Bispecific Antibody to Begin Clinical Development Utilizing Azymetric ™ and EFECT ™ Therapeutic Platforms

Full Press Release Details

Zymeworks Announces Second Janssen Bispecific Antibody to Begin Clinical Development Utilizing Azymetric ™ and EFECT ™ Therapeutic Platforms.

FDA Calendar

BPW Portfolio

Historical FDA Calendar

Market Movers

Biotech Earning Calendar

Historical PDUFA Dates

PDUFA Calendar

Conference Calendar

IPO

Catalyst Sync™

Hedge Fund Screener

Company Screener

All Stocks Holdings

Heat-Map

Inside Trades

Biotech Analyst Ratings

M&A Tracker

News

Blogs

Modality Leaderboard

Discord

User Guide

Biotech Investing 101

Recent Updates

Recently added Catalysts

Full Press Release Details